328.16 USD
-3.08 (-0.93%)
At close: Feb 6, 2026
324.01 USD
-4.15 (-1.26%)
After Hours: 2/6/2026, 8:17:35 PM
Overall ALNY gets a fundamental rating of 6 out of 10. We evaluated ALNY against 524 industry peers in the Biotechnology industry. ALNY has an average financial health and profitability rating. ALNY is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make ALNY a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
- ALNY had positive earnings in the past year.
- In the past year ALNY had a positive cash flow from operations.
- ALNY had negative earnings in each of the past 5 years.
- ALNY had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- ALNY has a better Return On Assets (0.90%) than 88.74% of its industry peers.
- The Return On Equity of ALNY (18.63%) is better than 95.42% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 6.34%, ALNY belongs to the top of the industry, outperforming 92.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.9% | ||
| ROE | 18.63% | ||
| ROIC | 6.34% |
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 1.36%, ALNY belongs to the top of the industry, outperforming 88.93% of the companies in the same industry.
- ALNY has a Operating Margin of 8.25%. This is amongst the best in the industry. ALNY outperforms 90.65% of its industry peers.
- The Gross Margin of ALNY (83.90%) is better than 86.64% of its industry peers.
- In the last couple of years the Gross Margin of ALNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.25% | ||
| PM (TTM) | 1.36% | ||
| GM | 83.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
- ALNY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- ALNY has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, ALNY has more shares outstanding
- The debt/assets ratio for ALNY has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 5.05 indicates that ALNY is not in any danger for bankruptcy at the moment.
- The Altman-Z score of ALNY (5.05) is better than 73.66% of its industry peers.
- ALNY has a debt to FCF ratio of 11.32. This is a negative value and a sign of low solvency as ALNY would need 11.32 years to pay back of all of its debts.
- The Debt to FCF ratio of ALNY (11.32) is better than 90.65% of its industry peers.
- A Debt/Equity ratio of 10.22 is on the high side and indicates that ALNY has dependencies on debt financing.
- With a Debt to Equity ratio value of 10.22, ALNY is not doing good in the industry: 81.11% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.22 | ||
| Debt/FCF | 11.32 | ||
| Altman-Z | 5.05 |
ROIC/WACC0.75
WACC8.5%
2.3 Liquidity
- ALNY has a Current Ratio of 2.54. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
- ALNY has a Current ratio of 2.54. This is in the lower half of the industry: ALNY underperforms 69.85% of its industry peers.
- ALNY has a Quick Ratio of 2.49. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
- ALNY has a Quick ratio of 2.49. This is in the lower half of the industry: ALNY underperforms 68.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.54 | ||
| Quick Ratio | 2.49 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 119.47% over the past year.
- The Revenue has grown by 53.24% in the past year. This is a very strong growth!
- ALNY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 59.21% yearly.
EPS 1Y (TTM)119.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.53%
Revenue 1Y (TTM)53.24%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%149.35%
3.2 Future
- The Earnings Per Share is expected to grow by 72.94% on average over the next years. This is a very strong growth
- Based on estimates for the next years, ALNY will show a very strong growth in Revenue. The Revenue will grow by 34.81% on average per year.
EPS Next Y209.79%
EPS Next 2Y130.23%
EPS Next 3Y102.21%
EPS Next 5Y72.94%
Revenue Next Year68%
Revenue Next 2Y55.75%
Revenue Next 3Y45.98%
Revenue Next 5Y34.81%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- ALNY is valuated quite expensively with a Price/Earnings ratio of 643.45.
- ALNY's Price/Earnings ratio is rather cheap when compared to the industry. ALNY is cheaper than 88.36% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.92. ALNY is valued rather expensively when compared to this.
- With a Price/Forward Earnings ratio of 45.82, ALNY can be considered very expensive at the moment.
- 90.46% of the companies in the same industry are more expensive than ALNY, based on the Price/Forward Earnings ratio.
- ALNY's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.78.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 643.45 | ||
| Fwd PE | 45.82 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, ALNY is valued cheaply inside the industry as 89.50% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, ALNY is valued cheaply inside the industry as 90.84% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 195.85 | ||
| EV/EBITDA | 131.79 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ALNY does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of ALNY may justify a higher PE ratio.
- ALNY's earnings are expected to grow with 102.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.07
PEG (5Y)N/A
EPS Next 2Y130.23%
EPS Next 3Y102.21%
5. Dividend
5.1 Amount
- ALNY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
328.16
-3.08 (-0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-12 2026-02-12/amc
Inst Owners99.97%
Inst Owner Change-1.59%
Ins Owners0.2%
Ins Owner Change8.99%
Market Cap43.35B
Revenue(TTM)3.21B
Net Income(TTM)43.56M
Analysts79.44
Price Target496.56 (51.32%)
Short Float %4.29%
Short Ratio3.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)103.88%
Min EPS beat(2)30.6%
Max EPS beat(2)177.15%
EPS beat(4)3
Avg EPS beat(4)65.69%
Min EPS beat(4)-2.21%
Max EPS beat(4)177.15%
EPS beat(8)7
Avg EPS beat(8)53.79%
EPS beat(12)10
Avg EPS beat(12)49.23%
EPS beat(16)10
Avg EPS beat(16)28.59%
Revenue beat(2)2
Avg Revenue beat(2)20.36%
Min Revenue beat(2)15.49%
Max Revenue beat(2)25.23%
Revenue beat(4)2
Avg Revenue beat(4)9.94%
Min Revenue beat(4)-0.56%
Max Revenue beat(4)25.23%
Revenue beat(8)4
Avg Revenue beat(8)11.04%
Revenue beat(12)7
Avg Revenue beat(12)14.54%
Revenue beat(16)8
Avg Revenue beat(16)8.99%
PT rev (1m)0.03%
PT rev (3m)6.49%
EPS NQ rev (1m)-5.16%
EPS NQ rev (3m)-31.18%
EPS NY rev (1m)27.26%
EPS NY rev (3m)71%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)-1.4%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)6.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 643.45 | ||
| Fwd PE | 45.82 | ||
| P/S | 13.51 | ||
| P/FCF | 195.85 | ||
| P/OCF | 163.07 | ||
| P/B | 185.35 | ||
| P/tB | 185.35 | ||
| EV/EBITDA | 131.79 |
EPS(TTM)0.51
EY0.16%
EPS(NY)7.16
Fwd EY2.18%
FCF(TTM)1.68
FCFY0.51%
OCF(TTM)2.01
OCFY0.61%
SpS24.3
BVpS1.77
TBVpS1.77
PEG (NY)3.07
PEG (5Y)N/A
Graham Number4.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.9% | ||
| ROE | 18.63% | ||
| ROCE | 8.03% | ||
| ROIC | 6.34% | ||
| ROICexc | 36.59% | ||
| ROICexgc | 36.59% | ||
| OM | 8.25% | ||
| PM (TTM) | 1.36% | ||
| GM | 83.9% | ||
| FCFM | 6.9% |
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.22 | ||
| Debt/FCF | 11.32 | ||
| Debt/EBITDA | 7.44 | ||
| Cap/Depr | 79.01% | ||
| Cap/Sales | 1.39% | ||
| Interest Coverage | 2.25 | ||
| Cash Conversion | 82.82% | ||
| Profit Quality | 508.12% | ||
| Current Ratio | 2.54 | ||
| Quick Ratio | 2.49 | ||
| Altman-Z | 5.05 |
F-Score5
WACC8.5%
ROIC/WACC0.75
Cap/Depr(3y)112.53%
Cap/Depr(5y)140.08%
Cap/Sales(3y)3.96%
Cap/Sales(5y)7.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.53%
EPS Next Y209.79%
EPS Next 2Y130.23%
EPS Next 3Y102.21%
EPS Next 5Y72.94%
Revenue 1Y (TTM)53.24%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%149.35%
Revenue Next Year68%
Revenue Next 2Y55.75%
Revenue Next 3Y45.98%
Revenue Next 5Y34.81%
EBIT growth 1Y240.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year558.53%
EBIT Next 3Y169.14%
EBIT Next 5Y135.27%
FCF growth 1Y432.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13193.2%
OCF growth 3YN/A
OCF growth 5YN/A
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
Can you provide the ChartMill fundamental rating for ALNYLAM PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to ALNY.
What is the valuation status for ALNY stock?
ChartMill assigns a valuation rating of 5 / 10 to ALNYLAM PHARMACEUTICALS INC (ALNY). This can be considered as Fairly Valued.
How profitable is ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
ALNYLAM PHARMACEUTICALS INC (ALNY) has a profitability rating of 6 / 10.
How financially healthy is ALNYLAM PHARMACEUTICALS INC?
The financial health rating of ALNYLAM PHARMACEUTICALS INC (ALNY) is 5 / 10.
What is the earnings growth outlook for ALNYLAM PHARMACEUTICALS INC?
The Earnings per Share (EPS) of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 209.79% in the next year.